Latest news with #Hikma
Jordan News
3 days ago
- Health
- Jordan News
Hikma Pharmaceuticals Donates $1.1 Million in Medical Aid to Syria - Jordan News
Hikma Pharmaceuticals PLC (Hikma) has donated $1.1 million worth of emergency medical supplies to Syria as part of a humanitarian initiative launched under royal directives and implemented by the Jordan Hashemite Charity Organization (JHCO). اضافة اعلان The medical convoy included essential medications such as antibiotics, painkillers, and a range of oral and hospital-use drugs, aimed at alleviating the acute shortage of medical supplies in Syria. This contribution reflects Hikma's ongoing commitment to its social and humanitarian responsibilities and its vision of delivering "better health, within reach, every day." The initiative builds on Hikma's longstanding support for relief and medical efforts both in Jordan and abroad, reinforcing its leadership as a Jordanian-based pharmaceutical company dedicated to serving communities and strengthening health systems especially in times of crisis and disaster.C
Makkah Newspaper
6 days ago
- Health
- Makkah Newspaper
Saudi Arabia's Pharma Leap to Global Leadership
Dear reader, over the past decade, Saudi Arabia has undertakenan ambitious overhaul of its healthcare and life sciences landscape. Guided by Vision 2030, the Kingdom is positioning itself as a knowledge‑driven economy with a robust, self‑reliant pharmaceutical sector. Recent data from IQVIA andEuromonitor highlight progress on several key fronts, including market expansion, manufacturing capacity, hospital infrastructure, and tender market dynamics. Here's a closer look at the numbers and why they matter. Across the broader Middle East and Africa (MEA) region, pharmaceutical sales increased from USD 24.2 billion in 2020 to USD 29.5 billion in 2023 and are projected to surpass USD 32.6 billion in 2024, representing a cumulative growth of approximately 35% over the four years. Saudi Arabia is the primary growth driver, with the Kingdom's share increasing from USD 8.7 billion to USD 11.6 billion, underscoring strong domestic demand and rising purchasing power. The UAE, SouthAfrica, and Algeria follow closely, while smaller markets, such as Lebanon, Jordan, and Kuwait, are expanding steadily from a lower base. Dear reader, Zooming in on Saudi Arabia's five largest therapy areas, combined sales rose from about USD 3.8 billion in 2019 to a forecasted USD 5.6 billion by 2026 (a 6.5 % compound annual growth rate). General medicines alone are expected to exceed USD 2.8 billion by 2026, followed by consumer health products at roughly USD 750 million, driven by trends in preventive care and wellness. Dermatology, digestive health, and ophthalmology remain smaller niches, but they are growing at 5–7% per year as urban lifestyles increase demand for allergy treatments and chronic disease medications. Government tenders remain the backbone of public procurement, valued at approximately USD 5.6 billion. Two multinationals, Hikma and Sanofi, lead with 9 % share each. Local champions SPIMACO (8%) and Tabuk Pharmaceuticals (7%) rank closely behind, while Pfizer, Novo Nordisk, and Novartis each hold 5–6%. At the other end of the scale, Jamejoom Pharma captures just 1 %, signaling headroom for domestic firms to ramp up portfolios tailored to tender specifications. Dear reader, domestic production is spreading across a broader base of players (over 2,100 registered items). Pharmaceutical Solution Industries (PSI) tops the chart with 21% of national output, followed by Tabuk (18%) and SPIMACO (15%).Jamejoom, Riyadh Pharma, and Jazeera Pharma each command roughly 8–9 %, while a long tail of other manufacturers together accounts for 20 %. The distribution highlights Ministry of Industry incentives to increase local content, promote innovation, and enhance exports, particularly following the launch of the National Biotechnology Strategy. Dear reader, several forces are converging: sweeping healthcarefinancing reforms, incentives for local manufacturing that deepen supply chain resilience, a welcoming stance toward foreign direct investment, and rapid digital adoption, from telemedicine to e-prescriptions. Although rising healthcare costs and chronic disease burdens pose challenges, current indicators suggest an ample runway for both local and international drugmakers, especially in biologics, targeted therapies, and self-care products. Saudi Arabia is charting a course to become the region's premier hub for pharmaceutical innovation and high‑quality healthcare services. With a sizable domestic market, expanding infrastructure, and policies favorable to private enterprise, the Kingdom could, by the end of the decade, rank among the most attractive healthcare markets in the broader Middle East and North Africa. In short, the 'Saudi pharma leap' is no longer aspirational rhetoric; it is unfolding on the ground. Continued execution will be vital, but the trajectory points to a future where Saudi Arabia not only meets local medical needs more efficiently but also exports health solutions to the world.
Web Release
16-07-2025
- Business
- Web Release
Hikma, IFC sign $250mn deal, marking a 40-year partnership driving access to quality medicines in the MENA region
Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, and the International Finance Corporation (IFC), a member of the World Bank Group, have signed a $250 million six-year financing agreement focused on expanding access to medicines to support Hikma's operations across the Middle East and North Africa region (MENA), by strengthening local medicine production. This financing builds on IFC's anchor role in Hikma's $500 million, five-year bond issuance, which included a $50 million subscription from IFC. The latest investments mark another milestone in a 40-year partnership and reaffirm IFC's commitment to supporting Hikma's mission of providing high-quality, affordable medicines across key MENA markets. Over four decades, IFC has offered Hikma financing and advisory tailored to the company's growth trajectory and helping reinforce its operational resilience. In 2017, IFC extended a loan to facilitate Hikma's regional expansion and later, in 2020, provided a financing package that enabled the uninterrupted distribution of medicines across the MENA region during the COVID-19 pandemic. 'Our longstanding partnership with IFC has supported our expansion into new markets over the past four decades, most recently through the strategic $250 million loan and contribution to our $500 million bond issuance. This has allowed us to respond effectively to critical healthcare needs in the regional markets we serve.' said Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA. 'Our partnership transcends monetary transactions and reflects our long-term alignment and shared values on corporate governance and sustainability. Together, we have grown strategically while staying focused on what matters most; supporting our patients by addressing high unmet healthcare needs across the region.' Hikma operates in over 50 countries across MENA, North America, and Europe, reporting revenues of over $3 billion in 2024. The company's growth has been driven by investments in local manufacturing and a series of strategic acquisitions and partnerships with multinational companies aimed at expanding access to high-quality medicines. Hikma has been listed on the London Stock Exchange since 2005 and was recognised in the FTSE4Good Index for ten consecutive years for its sustainability performance. In 2012, IFC honoured Hikma with its Client Leadership Award in recognition of its achievements in sustainability and corporate governance. Khawaja Aftab Ahmed, IFC's Regional Director for the Middle East, Pakistan, and Afghanistan, added: 'IFC's 40-year partnership with Hikma continues to demonstrate what's possible when global development institutions and private sector leaders collaborate. Together, we've expanded access to high-quality medicines across emerging markets, enabling the company to grow into new territories and deliver critical medicine when it was needed most, including during the COVID-19 pandemic. Our recent engagements build on that strong foundation and open the door for even greater impact by supporting local medicine production and continued regional growth, despite ongoing conflict and uncertainty.' The 40-year anniversary of our partnership was celebrated at Hikma's Amman headquarters on 14 July, with senior leaders and partners in attendance to honour their shared commitment to building stronger, more resilient health systems across the MENA region and beyond.
Ammon
01-07-2025
- Business
- Ammon
Hikma Pharmaceuticals to Invest $1B in U.S. Manufacturing & R&D Capabilities
Ammon News - Hikma Pharmaceuticals will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment will further expand Hikma's domestic capabilities to develop, produce and deliver a broad range of medicines. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The new phase of investment represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. 'We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients,' said Dr. Hafrun Fridriksdottir, President, Hikma Rx. 'Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.'
Daily Mail
30-06-2025
- Business
- Daily Mail
UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers
Medicines firm Hikma Pharmaceuticals plans to invest $1billion into US manufacturing and research and development over the next five years. The London-headquartered firm told investors on Monday the investment would expand its domestic capabilities 'to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide'. Hikma specialises in generic medicines - medications created to be the same as a brand-name drug, but usually sold at a lower cost. It comes as the UK-US trade deal comes into effect today, leaving UK carmakers with reduced tariffs of 10 per cent and removing levies on the aerospace sector entirely. However, Britain's pharmaceutical sector still faces the potential for further tariffs down the line, as well as recent suggestions the White House could move to clamp-down on the price of medicines in the US. UK pharma sold £6.6billion worth of products to the US last year, meaning the sector is Britain's second-biggest export to the country. President Donald Trump's threat to end exemptions on pharma tariffs, which are driven by a 1995 World Trade Organisation deal, has sparked fears that disruption to the sector's highly complex supply chain could have implications for UK pharmacies and patients. Hikma said on Monday it has provided access 'to a wide range of generic medicines at a lower cost than branded products' since operating in the US since 1991. The group's 'America Leans on Hikma' strategy plans to increase the volume of 'essential medicines' developed and produced across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and New Jersey. Hikma said: 'This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.' President of Hikma's generics business Dr. Hafrun Fridriksdottir added: 'We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients. 'Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.'
